Worth noting is that PCACs recommendations are not binding on the FDA, which must still undertake formal rulemaking before any substance is permanently added to the list
Evidence can be limited, mixed, preclinical, observational, old, formulation-specific, or otherwise insufficient to support an FDA-approved indication
Under current US compounding rules, pharmacies and outsourcing facilities may only compound medicines using active pharmaceutical ingredients (bulk drug substances) that form part of an FDA-approved medicine, appear in an official United States Pharmacopeia or National Formulary monograph, or are included on the FDAs bulk drug substance list
[3] This is one of the few genuinely controlled human GHK-Cu datasets, and it is a topical gel on an open wound
S., Muirhead, R
Learn more about storing peptides after reconstitution to keep everything organized